Skip to content

Clinical efficacy evaluation of scalp microenvironment improvement as adjuvant therapy for androgenic alopecia (AGA)

Clinical efficacy evaluation of scalp microenvironment improvement as adjuvant therapy for androgenic alopecia (AGA)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032745
Enrollment
Unknown
Registered
2020-05-09
Start date
2017-08-01
Completion date
Unknown
Last updated
2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

androgenic alopecia

Interventions

1:Scalp care treatment
2:finasteride and scalp care treatment

Sponsors

Department of Dermatology, Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. male between 18 and 40 years old; 2.. Patients with clinical symptoms such as excessive oil output, dandruff removal and hair loss in the past 3 months; 3. hair loss with type II to IV; 4. the degree of concern for the condition of hair is 'very concern' or 'extremely concern'.

Exclusion criteria

Exclusion criteria: 1. Clinical symptoms of scalp oil, dandruff and hair loss caused by other skin diseases such as psoriasis, infectious diseases, contact dermatitis, scalp folliculitis, etc.; 2. Patients with congenital alopecia areata, triangular alopecia and general alopecia. 3. people have received or is receiving medication or physical therapy for any skin disease or systemic disease in the recent (less than 3 months); 4. people is allergic to any component of the drug.

Design outcomes

Primary

MeasureTime frame
Scalp condition treatment index;Scalp monitoring indicators;

Countries

China

Contacts

Public ContactLin-feng Li

Beijing Friendship Hospital, Capital Medical University

zoonli@sina.com+86 13693620186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026